Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): Phase I safety and efficacy analyses Meeting Abstract
| Authors: | Kelley, R. K.; Abou-Alfa, G. K.; Bendel, J. C.; Kim, T. Y.; Borad, M. J.; Yong, W. P.; Morse, M.; Kang, Y. K.; Rebelatto, M.; Makowsky, M.; Xiao, F.; Morris, S. R.; Sangro, B. |
| Abstract Title: | Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): Phase I safety and efficacy analyses |
| Meeting Title: | 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 35 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2017 Jun 2-6 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2017-05-20 |
| Start Page: | 217s |
| Language: | English |
| ACCESSION: | WOS:000411895708157 |
| DOI: | 10.1200/JCO.2017.35.15_suppl.4073 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 4073 -- Source: Wos |
